1. Fibroblast growth factor 21 potently reduces atherosclerosis and NASH development. (August 2022) Authors: Liu, C.; Schönke, M.; Spoorenberg, B.; Lambooij, J.; Hendrik, V.D.Z.; Zhou, E.; Dekker, N.; Andréasson, A.-C.; Park, A.; Uhrbom, M.; Ahlstedt, I.; Ikeda, Y.; Wallenius, K.; Peng, X.-R.; Guigas, B.; Boon, M.; Wang, Y.; Rensen, P. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Fibroblast growth factor 21: A powerful therapeutic for hypercholesterolemia and atherosclerosis. (December 2020) Authors: Liu, C.; Schönke, M.; Zhou, E.; Li, Z.; Kooijman, S.; Larsson, M.; Wallenius, K.; Peng, X.-R.; Wang, Y.; Rensen, P. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Hepatic fibroblast growth factor 21 overexpression attenuates diet-induced hepatic steatosis and inflammation. (August 2021) Authors: Liu, C.; Schönke, M.; Zhou, E.; Larsson, M.; Wallenius, K.; Park, A.; Oldham, S.; Ikeda, Y.; Peng, X.-R.; Boon, M.R.; Wang, Y.; Rensen, P.C.N. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗